Myeloid Leukemia, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The putative targets: PROTEINASE 3, SURVIVIN, and hTERT were expressed only at relatively low levels by the CD34(+)CD38(-)ALDH(high) CML cells, similar to the normal CD34(+)CD38(-)ALDH(high) cells and less than in the total CML CD34(+) cells.
|
21132730 |
2011 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
LHGDN |
PR1-CTL responses detected in 7 of 28 CML patients before transplantation were not predictive of outcome and correlated inversely with PR3 and ELA2 expression.
|
17412886 |
2007 |
Myeloid Leukemia, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether eradication of CML after allogeneic stem cell transplantation (SCT) was influenced by PR3 and ELA2 gene expression or PR1-specific CTL responses, we studied cells from 87 CML patients and 27 HLA-A*0201(+) donors collected prior to T-cell-depleted HLA-identical sibling SCT.
|
17412886 |
2007 |
Myeloid Leukemia, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Other attractive targets are the Wilms' tumor 1 antigen and the PR1 epitope from proteinase 3, a granule protein overexpressed in CML.
|
20425356 |
2007 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In patients with CML in complete cytogenetic remission during IFN-alpha treatment, we detected some reactivity of CD8(+) T cells against BCR-ABL in IFN-gamma ELISPOT assays, which was weaker as compared with proteinase 3 (PR3)- or prame-directed responses, suggesting that the BCR-ABL protein is less immunogenic as compared with other CML-derived antigens.
|
16740729 |
2006 |
Myeloid Leukemia, Chronic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
|
16144796 |
2006 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
CTD_human |
Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
|
17157168 |
2006 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In human leukocyte antigen A*0201(+) (HLA-A*0201(+)) individuals, response after interferon-alpha (IFN-alpha) was shown to be associated with the emergence of CML-specific cytotoxic T cells that recognize PR-1, a myeloblastin (MBN)-derived nonapeptide.
|
12393722 |
2003 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have shown that cytotoxic T lymphocytes specific for PR1, an HLA-A2-restricted nonopeptide derived from proteinase 3, kill leukemia cells and may contribute to the elimination of chronic myelogenous leukemia (CML) after treatment with IFN or allogeneic bone marrow transplant.
|
12618518 |
2003 |
Myeloid Leukemia, Chronic
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Together, the induction of MBN expression by IFN-alpha, but not imatinib, may contribute to the specific ability of IFN-alpha to induce an MBN-specific T-cell response in CML patients.
|
12393722 |
2003 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using HLA-A2-PR1 tetramer analysis, we found that the frequency of T cells recognizing the PR1 epitope of proteinase 3 was not significantly different in allodepleted and unmanipulated PBMCs from patients with chronic myeloid leukemia (CML) undergoing transplantation.
|
12763937 |
2003 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data support the possibility that T-cell responses to allelic differences of proteinase 3 could be used as a basis for designing leukemia-specific adoptive T-cell therapy in acute and chronic myeloid leukemias.
|
9924693 |
1999 |
Myeloid Leukemia, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
|
9326217 |
1997 |